ALS driven by the C9orf72 hexanucleotide repeat expansion shows a fundamentally different glial response than sporadic ALS, despite near-identical clinical presentation. The findings by the team of Renzo Mancuso at the VIB-UAntwerp Center for Molecular Neurology, together with Philip Van Damme at KU Leuven/UZ Leuven, and the Van Den Bosch lab at the VIB-KU Leuven Center for Biology of Disease Research, were published in Nature Neuroscience.